Zenodo · Apr 14, 2026
Dasatinib Retrospective Validation: Computational Prediction Confirmed by Clinical Evidence — Ritschel Research scRNA-seq Drug Repurposing Pipeline
By Ritschel GC, Claude
RETRACTED (June 2026): The central claim of this document - that dasatinib's computational prediction was confirmed by clinical evidence - is retracted. The on-point SSc-ILD trial (PMC5679625) was negative on efficacy; the Alzheimer's and IPF trials cited are dasatinib plus quercetin senolytic safety/tolerability readouts, not efficacy confirmation; and recurrence across 8 pipelines reflects dasatinib's multi-kinase promiscuity, not 8 independent validations. What stands: dasatinib supports the SRC/ABL target rationale in scleroderma, but the compound underperformed clinically; the one real signal was molecular-subset stratification (p = 0.0455). See the full retraction notice in the current version of the document. The original version is preserved under its version DOI. This document is a standalone retrospective discussion, not a patent companion, and does not affect the validity or priority date of any Ritschel Research filing. The portfolio comprises 50 provisional filings (the "43" figure below is outdated). --- ORIGINAL DESCRIPTION (RETRACTED, preserved for the record) --- This document presents a retrospective validation of the Ritschel Research standardized scRNA-seq drug repurposing pipeline using dasatinib as a test case. Dasatinib is an FDA-approved BCR-ABL/SRC family kinase inhibitor with an established safety profile in chronic myeloid leukemia and acute lymphoblastic leukemia. The Ritschel Research pipeline independently identified dasatinib as a watchlist hit across 8 distinct disease pipelines — rheumatoid arthritis, ALS, IPF, inflammaging, scleroderma fibrosis, psoriatic arthritis, ankylosing spondylitis, and CKD — based solely on Wilcoxon differential expression analysis of publicly available human tissue scRNA-seq datasets and ChEMBL bioactivity screening. Published Phase 1 clinical trials subsequently confirmed dasatinib's activity in Alzheimer's disease and idiopathic pulmonary fibrosis via a senolytic mechanism, and preclinical SOD1/TDP-43 mouse model evidence confirmed activity in ALS. This retrospective concordance between computational prediction and independent clinical validation supports the biological validity of the pipeline methodology and, by extension, the novel drug candidates identified in the same disease contexts. All 43 patent specifications and companion preprints are archived on Zenodo under CC BY 4.0.